Particularly in cancers associated with chronic inflammation such as liver and colorectal cancers (Grivennikov et al., 2009; Park et al., 2010), STAT3 activation by growth factors or interleukins suppresses T cell activation and promotes the recruitment of anti-immunity factors such as myeloid-derived suppressor cells and regulatory T cells (Poschke et al., 2010; Tartour et al., 2011). This evidence concerns the gene STAT3 and colorectal cancer.